Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Nektar Therapeutics

2

Pfizer

420

Eli Lilly

237

Merck

216

GlaxoSmithKline

193

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Mu-type opioid receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2014

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Opioid-induced constipation

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Secondary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ChEMBL

2

DAILYMED

2

DRUG BANK

2

EPA CompTox

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR CONSTIPATION

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS FOR CONSTIPATION

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Peripheral opioid receptor antagonists

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

NALOXEGOL

44T7335BKE

Export Data
Search for Structure

Status:

US Approved Rx (2014)

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Mu-type opioid receptor

Conditions:

Opioid-induced constipation

MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as ...

a side effect of prescription opioid pain medicines.

NALOXEGOL OXALATE

65I14TNM33

Export Data
Search for Structure

Status:

US Approved Rx (2014)

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Mu-type opioid receptor

Conditions:

Opioid-induced constipation

MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as ...

a side effect of prescription opioid pain medicines.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1